Navigation Links
High dose UDCA therapy does not improve overall liver histology in obesity related hepatitis
Date:4/16/2010

Vienna, Austria, Friday 16 April: Results of a German study presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have shown that overall, treatment with high dose (23-28mg/kg/d) ursodeoxycholic acid (UDCA) is no more effective than placebo in the treatment of non-alcoholic steatohepatitis (NASH), the most advanced form of non-alcoholic liver disease associated with cirrhosis of the liver .

NASH is a serious development of non-alcoholic fatty liver disease (NAFLD), the most common persistent liver disorder in western countries and for which there is no proven medical therapy. Results from this study show that high dose UDCA a naturally occurring bile acid, historically used to treat gallstones is not superior to placebo therapy. Moderate histological and biochemical improvement was only observed in a subgroup of mildly overweight male patients.

Commenting on the study, Professor Fabio Marra of the EASL scientific committee said: "The use of UDCA is still considered controversial in non-alcoholic hepatitis, although previous research has suggested that the treatment may have some beneficial effects. The results of this study indicate that high dose UDCA is not superior to placebo except in a small subset of individuals. Nevertheless, the results do provide some interesting clinical pointers for clinicians in this field."

In the study, patients with histologically proven NASH (n=186, 147 of whom proceeded to treatment) were organised according to gender, body weight, liver biochemistry and histology and were randomised to receive either 23-28mg/kg/d UDCA or placebo for a period of 18 months.

Pre- and post-treatment liver biopsies from 139 patients were analysed, the primary evaluation criteria was an improvement in liver histology and secondary criteria were improvements in NASH-associated histological findings and liver function test results.

No significant difference was seen in overall liver histology or biochemistries between the two treatment groups. Interestingly, beneficial results were seen in intra-acinar inflammation (inflammation of the functional units of the liver) and levels of the enzyme gamma glutamyltransferase (a marker for liver cell damage) in a small population of younger, mildly overweight males, indicating that UDCA therapy may be potentially useful for these patients.

The incidence and prevalence of NASH is increasing , in parallel with rising levels of obesity one of the main risk factors for NASH . With this in mind, it is important to identify effective treatment options to improve the management of patients and prevent progression to cirrhosis an irreversible condition with liver transplant the only definitive treatment.


'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Related biology technology :

1. Seattle Facial Plastic Surgeon Among First In The Nation To Offer Ultherapy™
2. Cell Therapy Group Announces Expansion of Consultants Roster in Regenerative Medicine
3. Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
4. Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer
5. California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS
6. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
7. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
8. Progenitor Cell Therapy Expands Manufacturing Operations
9. Stroke Therapy with Corkscrew Device Most Beneficial, Study Suggests
10. Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries
11. Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Oxitec CEO Hadyn Parry will testify ... before the United States House Committee on Science, Space and ... controlling the spread of the Aedes aegypti mosquito, ... (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) Oxitec has pioneered ... in Brazil , Panama ...
(Date:5/23/2016)... Palo Alto, CA (PRWEB) , ... May 23, ... ... tank and public interest organization focused on molecular nanotechnology, announced the winners for ... honor of pioneer physicist Richard Feynman, are given in two categories, one for ...
(Date:5/20/2016)... ... May 20, 2016 , ... Kablooe Design, a leading provider of product design ... 25th anniversary of the business. “We have worked hard to build long-term relationships,” says ... the privilege and honor of serving their product design and development needs through the ...
(Date:5/19/2016)... ... May 19, 2016 , ... Anton Paar USA, located in Ashland, Virginia is ... complete. The new structure adds a third office building to the current facilities. ... 2.4 acres of land, along with office space adjacent to the previous main building. ...
Breaking Biology Technology:
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/18/2016)... March 18, 2016 --> ... Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter ... companies in the border security market and the continuing migration ... Europe has led visiongain to publish ... success. --> defence & security companies in ...
(Date:3/14/2016)... NXTD ) ("NXT-ID" or the "Company"), ... the airing of a new series of commercials on Time ... 21 st .  The commercials will air on Bloomberg TV, ... the Street show. --> NXTD ) ("NXT-ID" or ... market, announces the airing of a new series of commercials ...
Breaking Biology News(10 mins):